I used creatine 8 or so years ago, had great gains, ( it was the exact same product then & dont tell me its gotten better becasue its effervescent or some .) But I also had a frequent & uncomfortable need to urinate that was NOT just from consuming extra liquid, but from my kidneys being put on overload & doing damage to them with this stuff. I drank plenty of water, took a little less than the recommended dose & was having the urination problem for years after the use of creatine… I also was very short tempered with my family & young kids at the time I took it as it altered my mood.
I also have a friend who underwent a kidney transplant, that if he didnt get, he would have died . the reason for his kidney failure was creatine & he would tell you to stay far away from it as it almost costed him his life. This stuff is absolutely no good-
Disclaimer: The entire contents of this website are based upon the opinions of Dr. Mercola, unless otherwise noted. Individual articles are based upon the opinions of the respective author, who retains copyright as marked. The information on this website is not intended to replace a one-on-one relationship with a qualified health care professional and is not intended as medical advice. It is intended as a sharing of knowledge and information from the research and experience of Dr. Mercola and his community. Dr. Mercola encourages you to make your own health care decisions based upon your research and in partnership with a qualified health care professional. If you are pregnant, nursing, taking medication, or have a medical condition, consult your health care professional before using products based on this content.
The safety and pharmacokinetics of single-dose Xarelto (10 mg) were evaluated in a study in healthy subjects (n=16) and subjects with varying degrees of hepatic impairment (see Figure 2 ). No patients with severe hepatic impairment (Child-Pugh C) were studied. Compared to healthy subjects with normal liver function, significant increases in rivaroxaban exposure were observed in subjects with moderate hepatic impairment (Child-Pugh B) (see Figure 2 ). Increases in pharmacodynamic effects were also observed [see Use in Specific Populations () ] .